Know Cancer

or
forgot password

A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia


Phase 1/Phase 2
18 Years
N/A
Open (Enrolling)
Both
Myelodysplastic Syndrome, Acute Myeloid Leukemia

Thank you

Trial Information

A Phase 1/2 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients With Myelodysplastic Syndrome (RAEB-2) or With Previously Untreated Acute Myeloid Leukemia


All three drugs are FDA approved to treat patients in the United States of America.
Idarubicin and Cytarabine combination therapy is a standard treatment for patients with
acute myeloid leukemia (AML). Lenalidomide is FDA approved to retreat patients with Multiple
Myeloma or Myelodysplastic syndrome with a specific change in their DNA. Loss of a specific
part of DNA is also seen in some patients with AML.

This is a phase 1/2, dose-escalation trial of Lenalidomide given in combination with
idarubicin + cytarabine. During phase 1, we will enroll patients with AML involving del
5q31; 2) patients with MDS RAEB-2 associated with monosomy 5 or segmental deletion involving
5q31, either alone or with additional cytogenetic abnormalities, and 3) older patients with
any type of karyotypic profile in whom an effective and reliable standard of care remains to
be developed. All 3 groups of patients define a population of patients with very poor
prognoses. Dose escalation of lenalidomide will use a standard 3x3 design. Dose escalation
of Lenalidomide only will take place, while the doses of idarubicin and cytarabine will be
constant. This trial will have an induction component, consolidation component, and
maintenance component. Overall safety and MTD will be determined from the induction phase
only.

During phase 2, we will enroll only patients with AML age ≥ 60 years. During phase 2, the
efficacy of this combination of Lenalidomide + idarubicin + cytarabine, at the maximum
tolerated dose (MTD) for Lenalidomide (determined during phase 1), will be tested.


Inclusion Criteria:



- Understand and voluntarily sign an informed consent form

- Able to adhere to the study visit schedule and other protocol requirements

- Disease-specific criteria (Phase I):

- Previously untreated Acute Myeloid Leukemia (AML), associated with monosomy 5 or
segmental deletion involving 5q31, either alone or with additional cytogenetic
abnormalities

- Previously untreated AML (age ≥ 60 years)

- Myelodysplastic Syndrome, Refractory Anemia with Excess Blasts-2 (MDS,RAEB-2,
10-19% blasts in the bone marrow) associated with monosomy 5 or segmental
deletion involving 5q31, either alone or with additional cytogenetic
abnormalities

- For MDS, patients must have had progression with or failed response to
front-line therapy with a nucleoside analogue (azacitidine, decitabine).

- Disease Specific Criteria (Phase II)

- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 at study entry

- Left ventricular ejection fraction (LVEF) ≥ 50%

- Laboratory test results within these ranges:

- Serum creatinine ≤ 2.0 mg/dL

- Total bilirubin ≤ 1.5 mg/dL (Gilbert's syndrome excluded)

- Aspartic transaminase (AST) and Alanine transaminase (ALT) ≤ 2 x upper limit of
normal (ULN)

- Disease free of prior malignancies for ≥ 2 years with exception of currently treated
basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix
or breast

- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
and again within 24 hours of starting lenalidomide. For FCBP who have a medical need
to proceed with therapy immediately, the pregnancy test that would normally be done
10-14 days prior to initiation of lenalidomide may be done as late as 7 days prior to
initiation of lenalidomide. Both this test and the pregnancy testing done within 24
hours prior to initiation of lenalidomide must be negative. FCBP must either commit
to continued abstinence from heterosexual intercourse or begin TWO acceptable methods
of birth control, one highly effective method and one additional effective method AT
THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also
agree to ongoing pregnancy testing. Men must agree to use a latex* condom during
sexual contact with a FCBP even if they have had a successful vasectomy. All patients
must be counseled at a minimum of every 28 days about pregnancy precautions and risks
of fetal exposure. *For patients who have latex allergies or whose partner(s) have
latex allergies, alternatives will be discussed.

- Must be able to swallow capsules and no evidence of gastrointestinal (GI) tract
abnormality that would alter absorption of oral medications

- Understand and voluntarily sign an informed consent form

- Life expectancy >3 months

- All study patients must be registered into the mandatory RevAssist® program and be
willing and able to comply with the requirements of RevAssist®.

- Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again
within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be
filled within 7 days as required by RevAssist) and must either commit to continued
abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
control, one highly effective method and one additional effective method AT THE SAME
TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to
ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact
with a FCBP even if they have had a successful vasectomy. See Appendix: Risks of
Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control Methods.

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the patient from signing the informed consent form

- Pregnant or breast feeding females. (Lactating females must agree not to breast feed
while taking lenalidomide).

- Unwilling or unable to participate with Food and Drug Administration (FDA) mandated
birth control and pregnancy guidelines

- Any condition, including the presence of laboratory abnormalities, which places the
patient at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study

- Use of any other experimental drug or therapy within 28 days of baseline

- Known hypersensitivity to thalidomide

- The development of erythema nodosum, if characterized by a desquamating rash, while
taking thalidomide or similar drugs

- Any prior use of lenalidomide

- AML with cytogenetics including t(15;17), t(8;21), or inv(16)

- White blood count (WBC) count ≥ 50,000 on hydroxyurea therapy

- Previous history of induction chemotherapy for AML or allogeneic stem cell transplant

- Predicted inability to tolerate standard induction chemotherapy with idarubicin and
cytarabine

- History of spontaneous thromboembolic event requiring use of anticoagulation with
warfarin (coumadin) or low molecular-weight heparin within 3 years

- Known positive for human immunodeficiency virus (HIV) or infectious hepatitis, type
A, B or C

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Participants With Adverse Events (AEs) - Phase I Therapy

Outcome Description:

Rates of hematologic and non-hematologic toxicities of lenalidomide following idarubicin and cytarabine as induction therapy and as consolidation therapy. For the phase 1 component, no formal statistical analysis is planned. The primary endpoint is to assess safety and determine a recommended phase 2 dose of lenalidomide given in combination with standard idarubicin + cytarabine induction therapy.

Outcome Time Frame:

18 months

Safety Issue:

Yes

Principal Investigator

Jeffrey Lancet, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

H. Lee Moffitt Cancer Center and Research Institute

Authority:

United States: Institutional Review Board

Study ID:

MCC-15625

NCT ID:

NCT00831766

Start Date:

January 2009

Completion Date:

December 2013

Related Keywords:

  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia
  • Hematopoietic
  • Myeloid and Monocytic Leukemia
  • AML
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Myelodysplastic Syndromes
  • Preleukemia

Name

Location

H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida  33612
Cleveland Clinic - Taussig Cancer InstituteCleveland, Ohio  44195